Get the Stockscreener App
3.93
2.08%
0.08
After Hours:
3.94
0.010
+0.25%
Capricor Therapeutics Inc stock is traded at $3.93, with a volume of 3.35M.
It is up +2.08% in the last 24 hours and down -81.73% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$3.85
Open:
$3.85
24h Volume:
3.35M
Relative Volume:
1.80
Market Cap:
$227.59M
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-1.6991
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
-5.76%
1M Performance:
-81.73%
6M Performance:
-83.76%
1Y Performance:
-49.71%
1-Day Range:
$3.73
$3.998
1-Week Range:
$3.73
$4.70
52-Week Range:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
3.93 | 405.09M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
529.65 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.00 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
864.74 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.55 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - Yahoo Finance
Capricor Therapeutics Faces Severe Stock Decline Amid FDA Concer - GuruFocus
CAPR Investor Alert: Capricor Therapeutics Investors Encouraged t - The National Law Review
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR) - Seeking Alpha
Capricor Stock Tanks On FDA AdCom NotesWhat Investors Should Know (NASDAQ:CAPR) - Seeking Alpha
Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha
Alliance Global Partners Reiterates "Neutral" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63 - marketscreener.com
Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 - Moomoo
FDA panel raises doubts over Capricor’s deramiocel data ahead of DMD review - The Pharma Letter
CAPR|Capricor Therapeutics Inc|Price:7.000|Chg%:-12.700 - TradingKey
BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More - Supply Chain Digital
Biotech Firms Face Critical FDA Review Events - Intellectia AI
Capricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint - The Clinical Trial Vanguard
Capricor Therapeutics Inc (CAPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Securities Investigation on Behalf of Capricor Investors - ACCESS Newswire
B.Riley downgrades Capricor stock on FDA briefing concerns By Investing.com - Investing.com UK
Capricor addresses FDA briefing materials ahead of advisory meeting - Investing.com India
CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever - Stocktwits
Why Capricor Therapeutics (CAPR) Is Down 64.1% After FDA Flags Deramiocel Trial Concerns And Headquarters Bet - simplywall.st
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR - Business Wire
Capricor Therapeutics (CAPR) Faces FDA Advisory Vote Amid Steep Stock Decline - GuruFocus
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
CAPR Plunged About 64% After FDA Briefing Docs Hit. AdCom Is Wednesday. - Money Morning
FDA briefing casts doubt on Capricor’s deramiocel ahead of DMD AdCom - AllSci
Capricor Therapeutics (CAPR) Downgraded as FDA Briefing Raises A - GuruFocus
Capricor Therapeutics (CAPR) Shares Plunge Amid FDA Data Concerns, GF Score™ at 28 - GuruFocus
FDA staff report throws cold water on Capricor's DMD cell therapy bid - FirstWord Pharma
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T - The National Law Review
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpace
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by Roth Capital - MarketBeat
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Stocktwits
FDA staff flags data concerns about Capricor's therapy; shares plunge | Business Information & News | FE - Westlaw Today
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom By Investing.com - Investing.com Australia
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom - Investing.com
Investigation launched into Capricor Therapeuti... - Pluang
Market movers: Nvidia, Advanced Micro Devices, Capricor Therapeutics, SpaceX… - Proactive financial news
Capricor stock plunges 70% after FDA questions trial data for heart therapy. - Pluang
Capricor Therapeutics (CAPR) Prepares for FDA Advisory Committee Review on Deramiocel - GuruFocus
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC - GlobeNewswire
Capricor Therapeutics (CAPR) Shares Plunge 67% After FDA Briefin - GuruFocus
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target - Investing.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Benzinga
Capricor Therapeutics (CAPR) Stock Plummets 63% Amid FDA Advisor - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Capricor Therapeutics faces securities fraud pr... - Pluang
B.Riley downgrades Capricor stock on FDA briefing concerns - Investing.com
BREAKING: Capricor Therapeutics Investigated for Securities - GlobeNewswire
Capricor Therapeutics’ 67.7% collapse and the warning signs that preceded it - Investing.com
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.39%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):